Safety-77 Audit System
Providing Pharma with Safety Validation to Bypass Legacy Attrition.
De-Risking the Global Pipeline
By subjecting lead compounds to the proprietary 77 comprehensive in-silico profiling, the liabilities are identifed. These audits empower partners to move into Phase I human trials with unprecedented confidence.
ISTAND & NAMs Compliance
In direct alignment with the March 18, 2026 FDA Draft Guidance on New Approach Methodologies (NAMs), the Safety77 system is engineered for the ISTAND Permanent Program. This provides the computational proof required to satisfy modern regulatory expectations, helping customers transition away from animal reliance toward human-centric, in-silico safety evidence.
Credibility
"We exceed the FDA's 2026 AI Credibility Framework, ensuring every molecular rejection or promotion by the engine is backed by a rigorous 7-step validation process from 'Question of Interest' to 'Risk Assessment'."
> AUDIT STATUS: READY FOR EXTERNAL SUBMISSION
> TARGET PANEL: 77 LETHAL BIO-SENSORS
> _